Live Breaking News & Updates on Stephens Stakes

Stay updated with breaking news from Stephens stakes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

DermTech (NASDAQ:DMTK) Rating Reiterated by Stephens

DermTech (NASDAQ:DMTK – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Stephens in a research note issued on Friday, Benzinga reports. They presently have a $1.50 price objective on the stock. Stephens’ price target points to a potential upside of 132.92% from the company’s previous close. Separately, BTIG Research […] ....

United States , Dermtech Inc , Swiss National Bank , Dermtech Company Profile , Centaurus Financial Inc , Charles Schwab Investment Management Inc , Jpmorgan Chase Co , Get Free Report , Schwab Investment Management , National Bank , Dermtech Melanoma Test , Dermtech Daily , Nasdaq Dmtk , Reiterated Rating ,

Stephens Reaffirms "Overweight" Rating for CareDx (NASDAQ:CDNA)

Stephens reaffirmed their overweight rating on shares of CareDx (NASDAQ:CDNA – Free Report) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the stock. CareDx Stock Up 3.0 % Shares of CDNA stock opened at $8.31 on Wednesday. The firm has a market cap of $430.29 […] ....

United States , Investment Management , Bellevue Group , Caredx Inc , Blackrock Inc , Kent Lake Capital , Free Report , Get Free Report , Lake Capital , Street Corp , Allosure Kidney , Allomap Heart , Allosure Heart , Allosure Lung , Caredx Daily , Nasdaq Cdna , Reiterated Rating ,

OncoCyte's (OCX) Equal Weight Rating Reiterated at Stephens

Stephens reaffirmed their equal weight rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other research analysts have also commented on OCX. Benchmark reaffirmed a speculative buy rating and set a $5.00 price objective on […] ....

United States , Andrew Arno , Goldman Sachs Group Inc , Oncocyte Corporation , Cubist Systematic Strategies , Oncocyte Company Profile , Vanguard Group Inc , Securities Exchange Commission , Raymond James Financial Services Advisors Inc , Free Report , Cyte Stock Down , Director Andrew Arno , Exchange Commission , Broadwood Partners , James Financial Services Advisors , Sachs Group , Get Free Report , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Reiterated Rating ,

Old Second Bancorp's (OSBC) Overweight Rating Reaffirmed at Stephens

Stephens restated their overweight rating on shares of Old Second Bancorp (NASDAQ:OSBC – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. The firm currently has a $17.00 price target on the financial services provider’s stock. Separately, Raymond James upgraded Old Second Bancorp from an outperform rating to a strong-buy […] ....

Raymond James , Blackrock Inc , Old Second Bancorp Announces Dividend , Dimensional Fund Advisors , Vanguard Group Inc , Old Second Bancorp Price Performance , Old Second National Bank , Old Second Bancorp , Banc Funds Co , Old Second Bancorp Inc , News Ratings For Old Second Bancorp Daily , Free Report , Second Bancorp , Get Free Report , Fund Advisors , State Street Corp , Street Corp , Old Second Bancorp Daily , Nasdaq Osbc , Reiterated Rating ,